INTELLIA THERAPEUTICS INC's ticker is NTLA and the CUSIP is 45826J105. A total of 299 filers reported holding INTELLIA THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 1.39 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2023 | $308,040 | -34.1% | 10,103 | -31.6% | 0.22% | -38.2% |
| Q3 2023 | $467,249 | -24.1% | 14,777 | -2.1% | 0.36% | -11.1% |
| Q2 2023 | $615,411 | +18.8% | 15,091 | +8.5% | 0.40% | +11.3% |
| Q1 2023 | $518,202 | -3.3% | 13,904 | -9.5% | 0.36% | -18.4% |
| Q4 2022 | $536,000 | -34.2% | 15,371 | +5.6% | 0.44% | -35.5% |
| Q3 2022 | $815,000 | -80.9% | 14,558 | -82.4% | 0.69% | -29.7% |
| Q2 2022 | $4,270,000 | +446.7% | 82,499 | +667.4% | 0.98% | +86.1% |
| Q1 2022 | $781,000 | -27.7% | 10,751 | +17.7% | 0.53% | -27.7% |
| Q4 2021 | $1,080,000 | -9.4% | 9,134 | +2.8% | 0.73% | -11.4% |
| Q3 2021 | $1,192,000 | -20.5% | 8,886 | -4.0% | 0.82% | -19.3% |
| Q2 2021 | $1,499,000 | +86.9% | 9,256 | -7.4% | 1.02% | +28.6% |
| Q1 2021 | $802,000 | +210.9% | 9,994 | +110.9% | 0.79% | +154.2% |
| Q4 2020 | $258,000 | – | 4,739 | – | 0.31% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | 1,216,340 | $62,958,000 | 7.04% |
| Discovery Value Fund | 584,483 | $30,253,000 | 6.33% |
| MPM BioImpact LLC | 299,409 | $15,497,000 | 4.30% |
| ARK Investment Management | 9,514,580 | $439,003,000 | 2.60% |
| Elmwood Wealth Management, Inc. | 67,899 | $3,514,000 | 2.00% |
| Nikko Asset Management Americas, Inc. | 2,781,136 | $141,143,000 | 1.74% |
| Avidity Partners Management LP | 1,125,194 | $58,240,000 | 1.34% |
| Merlin Capital, Inc | 12,174 | $630,000 | 1.26% |
| Atlas Venture Associates IX, LLC | 10,000 | $518,000 | 1.18% |
| REGENTS OF THE UNIVERSITY OF CALIFORNIA | 111,440 | $5,768,000 | 1.16% |